Compound Radar

Haemonetics Corporation (HAE) Stock Analysis

United States · Healthcare / Medical Devices

Price $102.84
Market cap $4.68B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

74
74/100 High Quality
  • Financial Health 75
  • Profitability 75
  • Business Quality 75
  • Balance Sheet 55
  • Cash Flow 80

Why this rating?

Health 74/100 — High Quality

Strongest Cash Flow 80/100
Softest Balance Sheet 55/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Haemonetics Corporation (HAE) is a Medical Devices company in the Healthcare sector. Compound Radar rates Haemonetics Corporation 74/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 49.68
  • Forward P/E 17.92
  • PEG 1.63
  • EV/Revenue 4.17

Profitability

  • Revenue Growth 5.6%
  • Gross Margin 59.3%
  • Operating Margin 17.9%
  • Net Margin 7.1%
  • ROE 11.2%

Financial strength

  • Cash $224.52M
  • Debt $1.17B
  • Net Cash $-949.64M
  • Free Cash Flow $260.44M
  • Current Ratio 3.08

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks Haemonetics Corporation (HAE).

View Methodology & FAQ →